Overview of Downgrade#
BTIG has changed its rating for Embecta (NASDAQ:EMBC) from Buy to Neutral. This decision follows the company's disappointing second-quarter results, which were affected by a decline in market share for pen needles in the U.S. The stock is currently trading close to its 52-week low of $8.47, reflecting a 22% drop in value this year.
Financial Performance#
In the second quarter, Embecta reported revenue of $221.8 million and adjusted earnings per share (EPS) of $0.27. Both figures fell short of analyst expectations, which were $235.7 million for revenue and $0.42 for EPS. The company’s international sales were $126.4 million, while U.S. sales amounted to $95.4 million, missing the consensus estimate of $130.9 million.
Revised Guidance#
Embecta has lowered its full-year sales forecast by $57 million at the midpoint, despite anticipating around $30 million from its upcoming acquisition of Owen Mumford. The company also revised its adjusted operating margin outlook down to 22.25-23.25%, a decrease from the previous range of 29.0-30.0%. Furthermore, the adjusted EPS guidance has been reduced to a range of $1.55-$1.75, down from $2.80-$3.00.
Market Challenges#
The decline in Embecta’s performance is attributed to increased competition and lower demand for pen needles and syringes in the retail market. BTIG highlighted that a large customer has shifted to a lower-cost competitor, which has impacted Embecta's market share. The company is also facing potential challenges from greater patient access to GLP-1 drugs and the expiration of enhanced subsidies under the Affordable Care Act (ACA). The revised guidance reflects these ongoing market conditions, expected to persist through fiscal year 2026.